Cases of new-onset uveitis associated with infliximab
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
| Age (sex) | 84 (F) | 50 (F) | 14 (F) | 17 (M) |
| Disease | RA | RA | JIA | Crohn’s disease |
| Ocular involvement | Scleritis | Scleritis | Chronic iridocyclitis | None |
| Duration of systemic disease | 10 years | Unknown | Unknown | 2 years |
| New-onset uveitis | ME | Dense vitritis | ME | Retinal vasculitis ME |
| Duration of infliximab treatment before onset of ocular PAEs | 4 months | 5 months | 10 months | 2 years |
| Modification of anti-TNF | Switch to TCZ | Stop | Switch to ADA | Continued, then switch to ADA |
ADA, adalimumab;F, female;JIA, juvenile idiopathic arthritis;M, male;ME, macular oedema;PAE, paradoxical adverse effect;RA, rheumatoid arthritis;TCZ, tocilizumab;TNF, tumour necrosis factor.